A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

NCT01294683 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

977

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hypercholesterolemia
Dyslipidemia

Interventions

DRUG: Simvastatin
DRUG: Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)
DRUG: Extended Release (ER) niacin/laropiprant (N/LRPT)
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC